NUVL
Nuvalent Inc
NASDAQ: NUVL · HEALTHCARE · BIOTECHNOLOGY
$99.10
-2.79% today
Updated 2026-04-29
Market cap
$8.01B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-5.85
Dividend yield
—
52W range
$64 – $113
Volume
0.6M
Nuvalent Inc (NUVL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $9.75M | $15.40M | $35.56M | $63.73M | $113.24M | $217.77M | $306.97M |
| SG&A | $612000.00 | $1.50M | $10.26M | $22.38M | $36.25M | $62.59M | $107.34M |
| Operating income | $-10.36M | $-16.91M | $-45.82M | $-86.11M | $-149.49M | $-280.37M | $-414.31M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-11.81M | $-14.56M | $-46.12M | $-77.60M | $-126.22M | $-280.37M | $-10.48M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-10.36M | $-16.91M | $-45.82M | $-86.11M | $-149.49M | $-221.68M | $-424.79M |
| Interest expense | $0.00 | $0.00 | $521000.00 | $4.25M | $23.27M | $38.32M | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-11.81M | $-14.56M | $-46.34M | $-73.35M | $-126.22M | $-260.76M | $-425.38M |
| Net income growth (YoY) | — | -23.3% | -218.3% | -58.3% | -72.1% | -106.6% | -63.1% |
| Profit margin | — | — | — | — | — | — | — |